Single-Cell Insights Inform Clinical Trial Strategy for FHD-286 in Myeloid Malignancies
Challenge Foghorn Therapeutics was evaluating FHD-286, a dual BRG1/BRM inhibitor, in patients with relapsed/refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) as part of a multicenter Phase I study. To better understand the drug’s impact at the cellular level, the team needed high-resolution single-cell RNA sequencing (scRNA-seq) analysis of bone marrow aspirates. Given the complexity of AML… Read More »Single-Cell Insights Inform Clinical Trial Strategy for FHD-286 in Myeloid Malignancies
You must be logged in to post a comment.